TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000263967
  • Gene Name:PI3K
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:NA
  • Evidence:predicted
  • (mRNA-drug)

Drug basic information

  • Drug ID:NA
  • Drug Name:NA
  • Drug Method:NA

Disease basic infommation

  • Disease:laryngeal squamous cell cancer
  • Tissue:Two LSCC cell lines (Hep-2 and AMC-HN-8) and a normal human keratinocyte cell line 76 (HaCaT)

Other information

  • Title:MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway.
  • Journal:Eur J Pharmacol.
  • Published:2016
  • PubMed ID:27751825
  • Abstract:Increasing evidence indicates that the dysregulation of microRNAs is involved in tumor progression and development. The purpose of the present study was to explore the expression of microRNA-132 (miR-132) and its function in laryngeal squamous cell carcinoma (LSCC). The results showed that miR-132 expression was markedly upregulated in LSCC tissues and cell lines. Functional analyses indicated that overexpression of miR-132 enhanced cell proliferation and tumor growth, which resulted in the downregulation of p27 and p21 and the upregulation of cyclin D1. In addition, luciferase activity indicated that miR-132 directly targets FOXO1, and inhibits FOXO1 protein expression in LSCC cells. Further studies revealed that the ectopic expression of FOXO1 effectively reversed the cell growth induced by miR-132. Moreover, miR-132 also activated the PI3K/AKT pathway, which further decreased FOXO1 expression. In conclusion, these findings demonstrated that miR-132 plays an important oncogenic role in LSCC by modulating the PI3K/AKT/FOXO1 pathway at multiple levels, resulting in strong prognostic implication. Therefore, miR-132 might be a potential therapeutic strategy in LSCC.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3